FOLFOXIRI + Bevacizumab vs Doublets +Bevacizumab as Initial Therapy in Unresectable Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
J. Clin. Oncol 2020 Aug 20;[EPub Ahead of Print], C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, G Masi, E Ongaro, H Hurwitz, A Falcone, HJ Schmoll, M Di MaioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.